Sandoz launches EpiPen rival at $250 per two-pack


Sandoz has launched its epinephrine injection Symjepi. A twinpack will have a wholesale acquisition cost of $250, around 16.5% less than Mylan and Teva’s generic EpiPens.


Last July, Adamis Pharmaceuticals, developer of Symjepi, signed an exclusive U.S. distribution and commercialization deal with Sandoz, a division of Novartis. Adamis will share U.S. net profits with Sandoz.


Read the full article at…


Comments are closed.

Read previous post:
7 biopharma trends to watch in 2019

The industry's year ahead will be shaped by trends impacting biopharma's perception, investment and future growth. Criticism and scrutiny from...